NASDAQ:BNTC Benitec Biopharma Q1 2027 Earnings Date & Estimates $8.36 +0.25 (+3.08%) Closing price 10/19/2026 04:00 PM EasternExtended Trading$8.41 +0.05 (+0.59%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Benitec Biopharma is estimated to report Q1 2027 earnings on Friday, November 13, 2026, before market opens. The conference call is scheduled for 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ1 2027Announcement DateNovember 13, 2026TimeBefore Market OpensConference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Benitec Biopharma in Q1 2027Benitec Biopharma is expected to post earnings of -$0.2686 per share. In the same quarter a year earlier Benitec Biopharma reported -$0.22 per share. Benitec Biopharma last reported on September 14, 2026, posting -$0.26 per share and beating the -$0.2643 consensus estimate. Benitec Biopharma has beaten the consensus EPS estimate in 5 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.2686Prior-Year EPS-$0.22Recent Track RecordLast ReportedQ4 2026Last Quarter EPS-$0.26 (Beat by +$0.0043)EPS Beat Rate5 of last 7 quartersPrepare for the Q1 2027 CallEarnings HistoryCompany ProfileQ4 2026 Earnings ReportQ3 2026 Earnings ReportQ2 2026 Earnings Report Benitec Biopharma Q1 2027 Earnings FAQ When does Benitec Biopharma report Q1 2027 earnings? Benitec Biopharma (NASDAQ:BNTC) is estimated to report Q1 2027 earnings on Friday, November 13, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Benitec Biopharma's Q1 2027 earnings call? Benitec Biopharma's Q1 2027 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Benitec Biopharma? Analysts expect Benitec Biopharma to post earnings of -$0.2686 per share for Q1 2027. Benitec Biopharma Earnings HeadlinesBenitec Biopharma Limited (NASDAQ:BNTC) Stock Has Consensus Target Price of $24.00 According to BrokeragesOctober 11, 2026 | americanbankingnews.comBenitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal StudyOctober 5, 2026 | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 20 at 1:00 AM | Weiss Ratings (Ad)Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)September 16, 2026 | theglobeandmail.comWedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform RatingSeptember 15, 2026 | finance.yahoo.comBenitec Biopharma Files $200 Million Shelf RegistrationSeptember 15, 2026 | finance.yahoo.comSee More Benitec Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email. Email Address About Benitec BiopharmaBenitec Biopharma (NASDAQ:BNTC) (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines for chronic and potentially life-threatening diseases. The company’s work is based on DNA-directed RNA interference (ddRNAi), a gene-silencing technology designed to produce sustained suppression of disease-causing genes within targeted cells. Benitec’s lead investigational product is BB-301, an adeno-associated virus gene therapy being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive difficulty swallowing and weakness of the eyelid and throat muscles. BB-301 is designed to silence the mutated PABPN1 gene associated with OPMD while supporting production of a functional version of the gene. Founded in Australia in 1995, Benitec has developed its technology through research, licensing, and clinical-development activities and now operates as a U.S.-based biotechnology company. Its activities are focused primarily on advancing its gene-therapy pipeline through clinical studies and regulatory development rather than marketing commercial products.View Benitec Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Stock Has 2 New Reasons for Investors to Pay AttentionTesla's Roadster Reveal Hints at 2 Much Bigger MovesThe AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance AnywayRate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are DivergingMarketBeat Week in Review – 10/12 - 10/16Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?Could a Trucking Squeeze Become J.B. Hunt’s Biggest Edge? Upcoming Earnings Meta Platforms (10/21/2026)AT&T (10/21/2026)Tesla (10/21/2026)Philip Morris International (10/21/2026)Kinder Morgan (10/21/2026)CME Group (10/21/2026)Moody's (10/21/2026)Abbott Laboratories (10/21/2026)Danaher (10/21/2026)Elevance Health (10/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
